FDA denies inhaled migraine drug from Allergan

Allergan ($AGN) lost the latest bid for FDA approval of an inhaled version of the long-used drug dihydroergotamin for acute migraines. The U.S. regulator handed Allergan, which picked up the migraine therapy Levadex in its $958 million buyout of Map Pharmaceuticals last year, a complete response letter for its application for marketing approval, denying approval on concerns about manufacturing. Allergan, the maker of Botox, isn't giving up and recently wrapped up a buyout of a canister-filling outfit called Exemplar Pharma to address some of the manufacturing concerns. Article

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.